文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

康复者血浆治疗5例重症COVID-19患者

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
PubMed 文献 · JAMA · 2020-01-01
一句话结论5例重症COVID-19合并ARDS患者输注含中和抗体的康复者血浆后临床状态改善,但样本量有限且为无对照病例系列,需临床试验评估。

该研究为深圳第三人民医院感染科2020年1月20日至3月25日的5例危重型COVID-19合并ARDS患者的病例系列,所有患者均接受机械通气、抗病毒药物及甲泼尼龙治疗,并输注SARS-CoV-2特异性IgG结合滴度大于1:1000且中和滴度大于40的康复者血浆。输注后4/5患者体温3天内恢复正常,SOFA评分下降,PaO2/FiO2在12天内升高(输注前172-276,输注后284-366),病毒载量下降并于12天内转阴,抗体滴度升高(输注前40-60,第7天80-320),4例ARDS消退,3例2周内脱机,3例出院。作者结论为初步无对照病例系列提示临床状态改善,但样本量有限和研究设计所限不能对疗效作出确定性结论,需临床试验评估。

要点

  • 5例危重型COVID-19合并ARDS患者均接受机械通气、抗病毒药物及甲泼尼龙治疗,并输注SARS-CoV-2特异性IgG结合滴度大于1:1000且中和滴度大于40的康复者血浆。
  • 输注后4/5患者体温3天内恢复正常,SOFA评分下降,PaO2/FiO2在12天内升高(输注前172-276,输注后284-366)。
  • 病毒载量下降并于输注后12天内转阴,SARS-CoV-2特异性ELISA及中和抗体滴度升高(输注前40-60,第7天80-320)。
  • 4例患者在输注后12天ARDS消退,3例在治疗2周内脱机,3例出院(住院时间53、51、55天),2例在输注后37天病情稳定。
  • 作者结论为初步无对照病例系列,样本量有限和研究设计所限不能对疗效作出确定性结论,需临床试验评估。

适用人群与场景

  • 实验室确诊COVID-19并符合ARDS的危重型患者,纳入标准为:重症肺炎快速进展且抗病毒治疗后病毒载量持续高、PaO2/FiO2小于300、接受机械通气。
  • 研究在深圳第三人民医院感染科进行,时间为2020年1月20日至3月25日,末次随访日期为2020年3月25日。

诊断标准与关键阈值

  • ARDS诊断标准未在原文中详细列出。
  • 康复者血浆输注标准:SARS-CoV-2特异性抗体(IgG)结合滴度大于1:1000(终点稀释滴度,采用酶联免疫吸附试验[ELISA]检测)且中和滴度大于40(终点稀释滴度),血浆来自5例COVID-19康复患者。

处置流程与药物剂量

  • 所有患者均接受抗病毒药物和甲泼尼龙治疗(剂量原文未写明)。
  • 所有患者接受机械通气,部分患者接受体外膜肺氧合(ECMO)支持(具体例数原文未写明)。
  • 康复者血浆在入院后10至22天输注(剂量、输注频次及疗程原文未写明)。

研究设计与关键结果

  • 研究类型为病例系列,纳入5例危重型COVID-19合并ARDS患者(年龄36-65岁,2例女性),均接受机械通气、抗病毒药物及甲泼尼龙治疗,并输注康复者血浆。
  • 输注后4/5患者体温3天内恢复正常;SOFA评分下降;PaO2/FiO2在12天内升高(输注前172-276,输注后284-366)。
  • 病毒载量下降并于输注后12天内转阴;SARS-CoV-2特异性ELISA及中和抗体滴度升高(输注前40-60,第7天80-320)。
  • 4例患者在输注后12天ARDS消退,3例在治疗2周内脱机。
  • 5例中3例出院(住院时间分别为53、51、55天),2例在输注后37天病情稳定。

证据类型、等级与局限

  • 证据类型:病例系列(初步、无对照)。
  • 局限:原文报告样本量有限和研究设计所限不能对疗效作出确定性结论,这些观察需在临床试验中评估。

对床旁实践的改变

  • 作者认为,在5例危重型COVID-19合并ARDS患者的初步无对照病例系列中,输注含中和抗体的康复者血浆后临床状态改善。
  • 作者指出,样本量有限和研究设计所限不能对疗效作出确定性结论,这些观察需在临床试验中评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.

OBJECTIVE: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

DESIGN, SETTING, AND PARTICIPANTS: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 <300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.

EXPOSURES: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.

MAIN OUTCOMES AND MEASURES: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.

RESULTS: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.

CONCLUSIONS AND RELEVANCE: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020. PMID: 32219428. doi:10.1001/jama.2020.4783

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。